Fundraising Fox
Ampersand Biomedicines
3 known investors
Find your way into Ampersand Biomedicines
Ampersand Biomedicines develops programmable, multi-specific biologic therapies designed to act only at the site of disease, aiming to reduce off-tissue side effects and toxicities. It uses a computational platform and proprietary "Address Map" to identify localizing targets and design its modular medicines.
Investors · 3
Flagship Pioneeringlisted by Flagship PioneeringCambridge · $500K – $10M
How we know: Flagship Pioneering's portfolio page · a partner's Signal profile · funding news · globenewswire.com · Not right? Tell us
Also in the syndicate · 2
Eli Lilly & CompanyEli Lilly and Company
Funding
SEC filings, press & company announcements$65M disclosed across 1 round · 2025
- $65MSeries BMar 2025 · 4 sources
Eli Lilly & Company, Eli Lilly and Company, Flagship Pioneering
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Ampersand Biomedicines went on to found or lead other companies.
Frequently asked questions
- What does Ampersand Biomedicines do?
- Ampersand Biomedicines develops programmable, multi-specific biologic therapies designed to act only at the site of disease, aiming to reduce off-tissue side effects and toxicities. It uses a computational platform and proprietary "Address Map" to identify localizing targets and design its modular medicines.
- Who are Ampersand Biomedicines's investors?
- Ampersand Biomedicines's investors include Flagship Pioneering.
- How much funding has Ampersand Biomedicines raised?
- Ampersand Biomedicines has disclosed $65M raised across 1 round.